Retatrutide

Retatrutide Struktur
2381089-83-2
CAS-Nr.
2381089-83-2
Englisch Name:
Retatrutide
Synonyma:
LY3437943;Retalutide;GIPR/GLP-1R;Retatrutide;Retaglutide;Retatratide;retatrutide 5mg;Retatrutide RT5;Retatrutide acetate;retatrutide peptide
CBNumber:
CB912574543
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

Retatrutide Eigenschaften

storage temp. 
-20°C
Aggregatzustand
powder
Farbe
White lyophilized
Wasserlöslichkeit
Soluble in water (5mg/ml).

Sicherheit

Retatrutide Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.
Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.
Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.
Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

Biologische Aktivität

Retatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependent insulinotropic polypeptide (GIP)[7].

Nebenwirkungen

The most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.

Retatrutide Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Retatrutide Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 119)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shanghai Longyu Biotechnology Co., Ltd.
+8619521488211
info@longyupharma.com China 2534 58
Hubei Yuanao Technology CO Ltd
+86-15377628618 +86-15377628618
info@yuanaotech.com China 6 58
CONTIDE BIOTECH CO.,LTD
+852-53358525
xena@healthtide-api.com China 568 58
Hebei Xunou new energy Technology Co., LTD
+undefined17531957005
xunou8@hbxunou.com China 36 58
Hebei Anlijie Biotechnology Co., Ltd
+8619031013551
ably@aljbio.com China 145 58
Hebei Yalin Technology Co., Ltd
+86-19322905052 +86-19322905052
yl01@ylmetallurgy.com China 9 58
Hebei Lingding Biotechnology Co., Ltd.
+86-18031140164 +86-19933155420
erin@hbldbiotech.com China 5 58
Shanghai Affida new material science and technology center
+undefined15081010295
admin@oudaxin.com China 114 58
hebei hongtan Biotechnology Co., Ltd
+86-86-1913198-3935 +8617331935328
sales03@chemcn.cn China 973 58
Sea Biological Co.,LTD
+86-13865152372 +86-13865152372
tim@sea-biol.com China 71 58

  • LY3437943
  • Retatrutide
  • GIPR/GLP-1R
  • Retatrutide/LY3437943/GIPR/GLP-1R
  • Retaglutide
  • Retatrutide acetate
  • LY3437943Retatrutide
  • Retatrutide (sodium salt)
  • Retalutide
  • Retatrutide RT5
  • retatrutide 5mg
  • Retatratide
  • retatrutide peptide
  • 2381089-83-2
Copyright 2019 © ChemicalBook. All rights reserved